Novo Nordisk, a global healthcare company, agreed to acquire Cardior, a company that discovers and develops therapies that target RNA as a means to prevent, repair and reverse diseases of the heart, for €1.025bn. “By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programmes across all phases of clinical development. We have been impressed by the scientific work carried out by the Cardior team, especially on CDR132L, which has a distinctive mode of action and potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people living with heart failure,” Martin Holst Lange, Novo Nordisk Executive Vice President.